The global digital dose inhalers market was valued at US$ 2.23 Bn in 2021 and is projected to advance at a CAGR of 12.5% from 2022 to 2031. The global digital dose inhalers market is anticipated to reach more than US$ 7.22 Bn by 2031.
Digital Dose Inhalers Market Introduction
Digital dose inhalers are advanced, smart devices intended to treat and manage drug delivery for various respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Digital dose inhalers are used to provide a simple, accurate, and reliable dose counter, which enables patients to track adherence to their therapy. Increase in patient population, adoption of novel technologies, and surge in research & development in developed and developing countries are driving the global digital dose inhalers market.
Get Sample Copy of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18881
Furthermore, rise in prevalence of respiratory diseases such as asthma and COPD (chronic obstructive pulmonary disorder) across the globe and increase in geriatric population are projected to drive the global digital dose inhalers market in the next few years. Thus, demand for digital inhalers for chronic obstructive pulmonary disease is anticipated to increase substantially across the globe. Introduction of data integration with EHR (electronic health records) or EMR (electronic medical records) is a major trend in the global digital dose inhalers market.
Emerging economies such as India, China, Brazil, and Mexico offer significant opportunities in the global digital dose inhalers market. Presence of large geriatric population; government initiatives to improve healthcare sector; rise in research & development activities; and increase in pollution, allergens, and occupational dust are factors driving the market in these countries.
Increase in Awareness and Penetration Augmenting Demand for Metered Dose Inhalers
In terms of product, the metered dose inhalers segment accounted for major share of the global digital dose inhalers market in 2021. This can be ascribed to the rise in penetration and product launch of metered dose inhalers; and increase in awareness about these products among patients. According to NCBI, the inherent multi-dose nature of MDIs makes them more affordable than most competing inhalation delivery systems. Thu, metered dose inhalers are considered highly popular inhalers to treat local respiratory diseases such as asthma and COPD.
Increase in regulatory approvals is driving the metered dose inhalers segment. For instance, in December 2018, AstraZeneca received approval from the European Commission (EC) for Bevespi Aerosphere, which is used in a pressurized metered dose inhaler (pMDI) indicated as maintenance dual bronchodilator treatment in adult patients with COPD. This approval enabled the company to add a technologically advanced product to its existing product offerings for patients in Europe.
Get Report Methodology @ https://www.transparencymarketresearch.com/sample/sample.php?flag=RRM&rep_id=18881
High Prevalence of Asthma to Boost Digital Dose Inhalers Market
In terms of application, the asthma segment accounted for significant share of the global digital dose inhalers market in 2021. This can be ascribed to high prevalence and product launches. According to the WHO, asthma was a major non-communicable disease in 2019. Asthma affected an estimated 262 million people and caused 455,000 deaths in 2019. According to the Asthma and Allergy Foundation of America, more than 26 million people in the U.S. suffer from asthma. Incidence of asthma has been increasing since the early 1980s in all ages, sexes, and racial groups.
Rise in launch of digital inhalers for asthma is driving the asthma segment. For instance, in January 2017, Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) approved two of its products for adolescent and adult patients with asthma. These products, i.e. AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAir RespiClick (fluticasone propionate inhalation powder), include medication delivered via Teva’s RespiClick breath-activated, multi-dose dry powder inhaler (mDPI), which is also used with other approved medicines from Teva’s respiratory inhaler product portfolio.
Regional Outlook of Global Digital Dose Inhalers Market
North America dominated the global digital dose inhalers market in 2021. The region’s dominance of the global market can be ascribed to high prevalence and increase in incidence of COPD and asthma in the U.S. and Canada; well-established healthcare infrastructure; and high risk of lifestyle-related diseases. Furthermore, increase in trend of smoking in North America is propelling the risk of asthma. Smoking is directly responsible for around 90% of lung cancer deaths and nearly 80% of deaths caused by chronic obstructive pulmonary disease (COPD) including emphysema and chronic bronchitis. Additionally, robust product pipeline of key players is projected to drive the global digital dose inhalers market in North America.
Asia Pacific is anticipated to be the fastest growing market for digital dose inhalers during the forecast period. China dominated the digital dose inhalers market in the region in 2021. The digital dose inhalers market in India is likely to grow at a high CAGR during the forecast period. According to Lung India, a recent Indian study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis (INSEARCH) conducted on 85,105 men and 84,470 women from 12 urban and 11 rural sites in India, the rate of prevalence of asthma in India stands at 2.05% among individuals aged over 15 years, with a burden of around 18 million asthma patients across the country.
The digital dose inhalers market in Latin America and Middle East & Africa is likely to grow at a decent CAGR owing to the increase in respiratory disease patient pool and focus of manufacturers on the development of novel products.
Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=18881
Analysis of Key Players in Global Digital Dose Inhalers Market
This report includes vital information about the key players operating in the global digital dose inhalers market. Digital dose inhaler companies are focusing on strategies such as new product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market.
Leading players analyzed in the report are –
- Novartis AG,
- GlaxoSmithKline plc,
- Teva Pharmaceutical Industries Ltd.,
- Sensirion AG Switzerland,
- AptarGroup, Inc.,
- Cipla, Inc.,
- H&T Presspart Manufacturing Ltd
Key Developments in Global Digital Dose Inhalers Market
In March 2022, the U.S. Food and Drug Administration gave the approval for the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions to Mylan Pharmaceuticals, Inc.
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
USA – Canada Toll Free: 866-552-3453